Outcomes of Older Men Receiving Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer

BACKGROUND: Most men who die of prostate cancer are older than 70 years. The ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) randomized men of all ages with metastatic hormone-sensitive prostate cancer (mHSPC) to receive androgen de...

Descripción completa

Detalles Bibliográficos
Autores principales: Lage, Daniel E., Michaelson, M. Dror, Lee, Richard J., Greer, Joseph A., Temel, Jennifer S., Sweeney, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599519/
https://www.ncbi.nlm.nih.gov/pubmed/34007017
http://dx.doi.org/10.1038/s41391-021-00389-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599519/
https://www.ncbi.nlm.nih.gov/pubmed/34007017
http://dx.doi.org/10.1038/s41391-021-00389-2

Ejemplares similares